Feng Zhao1, Chan Li2, Yun Wu3, Jianling Xia1, Ming Zeng1, Tao Li4, Ke Xie1. 1. Oncology Clinical Department, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu 611731, China. 2. Southwest Medical University, People's Hospital of Xinjin, Chengdu 611430, China. 3. Medical School, University of Electronic Science and Tech, Chengdu 611731, China. 4. Southwest Medical University, Sichuan Cancer Hospital and Institute, Chengdu 610041, China.
Abstract
AIM: A meta-analysis was conducted to estimate the impact of connective tissue growth factor (CTGF) on outcomes in patients with digestive system cancers. METHODS: A systemic literature survey was performed by searching the Cochrane Library and PubMed databases for articles that evaluated the impact of CTGF on outcomes in patients with digestive system cancers. Hazard ratios and 95% confidence intervals were calculated for prognostic factors, overall and recurrence-free survival using RevMan 5.3 software. RESULTS: This meta-analysis was conducted to evaluate a total of 11 studies that included 1730 patients. The results showed that elevated CTGF expression was significantly correlated with advanced age, larger tumor size, multiple tumors, and vascular invasion. Subgroup analysis by cancer type revealed increased risk for lymph node metastasis and advanced tumor node metastasis (TNM) stage in gastric cancer, compared with colorectal cancer. An unfavorable effect of elevated CTGF levels on overall survival was found in patients with hepatocellular carcinoma and patients with gastric cancer, while survival was improved in colorectal cancer patients with high CTGF expression, compared to those with normal levels of CTGF. CONCLUSIONS: Elevated CTGF expression may be a novel biomarker for disease status and predicted survival outcomes in patients with specific digestive system cancers.
AIM: A meta-analysis was conducted to estimate the impact of connective tissue growth factor (CTGF) on outcomes in patients with digestive system cancers. METHODS: A systemic literature survey was performed by searching the Cochrane Library and PubMed databases for articles that evaluated the impact of CTGF on outcomes in patients with digestive system cancers. Hazard ratios and 95% confidence intervals were calculated for prognostic factors, overall and recurrence-free survival using RevMan 5.3 software. RESULTS: This meta-analysis was conducted to evaluate a total of 11 studies that included 1730 patients. The results showed that elevated CTGF expression was significantly correlated with advanced age, larger tumor size, multiple tumors, and vascular invasion. Subgroup analysis by cancer type revealed increased risk for lymph node metastasis and advanced tumor node metastasis (TNM) stage in gastric cancer, compared with colorectal cancer. An unfavorable effect of elevated CTGF levels on overall survival was found in patients with hepatocellular carcinoma and patients with gastric cancer, while survival was improved in colorectal cancer patients with high CTGF expression, compared to those with normal levels of CTGF. CONCLUSIONS: Elevated CTGF expression may be a novel biomarker for disease status and predicted survival outcomes in patients with specific digestive system cancers.
Authors: A Gardini; B Corti; M Fiorentino; A Altimari; G Ercolani; G L Grazi; A D Pinna; W F Grigioni; A D'Errico Grigioni Journal: Dig Liver Dis Date: 2005-01-07 Impact factor: 4.088
Authors: Wei Kang; Tingting Huang; Yuhang Zhou; Jinglin Zhang; Raymond W M Lung; Joanna H M Tong; Anthony W H Chan; Bin Zhang; Chi Chun Wong; Feng Wu; Yujuan Dong; Shiyan Wang; Weiqin Yang; Yi Pan; Wing Po Chak; Alvin H K Cheung; Jesse C S Pang; Jun Yu; Alfred S L Cheng; Ka Fai To Journal: Cell Death Dis Date: 2018-01-24 Impact factor: 8.469